The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer
Authors
Keywords
-
Journal
OncoImmunology
Volume 6, Issue 9, Pages e1323619
Publisher
Informa UK Limited
Online
2017-05-17
DOI
10.1080/2162402x.2017.1323619
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives
- (2016) Insa Schiffmann et al. Epigenetics
- Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer
- (2016) Kari E. Hacker et al. Journal of the National Comprehensive Cancer Network
- DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
- (2015) David Roulois et al. CELL
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial
- (2015) Sven Mahner et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
- (2015) Joon Hyeok Lee et al. GASTROENTEROLOGY
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma
- (2015) Qian Mei et al. Oncotarget
- Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
- (2015) Erika Héninger et al. Frontiers in Immunology
- Decitabine reactivated pathways in platinum resistant ovarian cancer
- (2015) Fang Fang et al. Oncotarget
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
- (2014) R M Glasspool et al. BRITISH JOURNAL OF CANCER
- Maintenance Therapy With Autologous Cytokine-induced Killer Cells in Patients With Advanced Epithelial Ovarian Cancer After First-line Treatment
- (2014) Jun Liu et al. JOURNAL OF IMMUNOTHERAPY
- A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
- (2013) I. Garrido-Laguna et al. INVESTIGATIONAL NEW DRUGS
- Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- How to approach patients in relapse
- (2012) E. Pujade-Lauraine ANNALS OF ONCOLOGY
- Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study
- (2012) Runmei Li et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- Randomized Study of Autologous Cytokine-Induced Killer Cell Immunotherapy in Metastatic Renal Carcinoma
- (2012) L. Liu et al. CLINICAL CANCER RESEARCH
- Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
- (2012) David M. Gershenson et al. GYNECOLOGIC ONCOLOGY
- Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
- (2012) C Zeller et al. ONCOGENE
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
- (2011) Wei-Ting Hwang et al. GYNECOLOGIC ONCOLOGY
- Clinical Trials in Recurrent Ovarian Cancer
- (2011) Michael Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
- (2010) Siqing Fu et al. CANCER
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
- (2008) Gabriella Ferrandina et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started